IMMUNOVANT, INC. (IMVT) Net income 2019–2026
IMMUNOVANT, INC. (IMVT) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$505.6MFY2026 · since FY2019: -$28.6M → -$505.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$505.6M | -22.2% |
| FY2025 | -$413.8M | -59.6% |
| FY2024 | -$259.3M | -22.9% |
| FY2023 | -$211.0M | -34.6% |
| FY2022 | -$156.7M | -45.9% |
| FY2021 | -$107.4M | -61.8% |
| FY2020 | -$66.4M | -132.1% |
| FY2019 | -$28.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More IMVT financial trends
IMVT RevenueIMVT Net marginIMVT Gross profitIMVT Gross marginIMVT Operating incomeIMVT Operating marginIMVT Operating cash flowIMVT Free cash flowIMVT Capital expendituresIMVT Return on equityIMVT Stock buybacksIMVT Dividends paidIMVT Total assetsIMVT Total liabilitiesIMVT Shareholders’ equityIMVT overview →